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An obesity epidemic booga booga?
Currently, one-fifth of Western
Europeans have a body mass index
(BMI) 30 kg/m2, a common definition
of obesity. On one hand, the increasing
prevalence of obesity during the last
decades has been reported as a ‘major
public health issue’, a ‘21st century
pandemic’, up to an apocalyptic ‘obesity
tsunami’. Others consider that the
trend will induce consequences compar-
able with global warming. The foresee-
able response to these frightening
messages has been an upsurge of task
forces, committees and agencies that are
planning ambitious campaigns against
high BMI.
On the other hand, some experts
state that the epidemic of obesity is
exaggerated,1 is merely the expression of
a subtle shift in the distribution of BMI2
and, eventually, that there is no epidem-
ic.2,3 Further, all the noise about obesity
and its consequences have fuelled obses-
sions about body weight in the popula-
tion—a dieting epidemic—but also
confusion on the real consequences of
obesity. In response to this ‘obesity
epidemic booga booga’,4 fat acceptance,
anti-dieting and health-at-every-size-
movements have gained importance to
recall that some excess fat does not
mean necessarily bad health and to fight
prejudice and discrimination against
obese people.
In this point of view, we argue that
dramatization of obesity could blur
the public health issues at stake. No
doubt that mean BMI has increased and
that obesity is more frequent than
previously. Still, a careful evaluation
of the genuine consequences of BMI
trends on the health of populations
is needed. This requires addressing
issues about the nosological status
of obesity and its causal role on
associated conditions.
Clinical vs population
consequences of obesity
Let us first paraphrase one of the Rose’s
paradigm: ‘clinical’ (or individual) con-
sequences of overweight and obesity
may be distinct from ‘population’ con-
sequences. In other words, the impact of
obesity on population health is likely to
differ from its consequences at individ-
ual level. The latter are well described,
e.g. hypertension, type 2 diabetes,
cardiovascular diseases (CVDs), osteo-
arthritis and several cancers, as well as,
probably, depression.
At the population level, the impact
of obesity is much more difficult to
characterize.5 While rising diabetes
trends, a major threat at population
level, have clearly paralleled rising obes-
ity trends in many countries, hyperten-
sion or dyslipidaemia have not.6
For instance, mean blood pressure
decreased regularly between the mid-
1980s and the mid-1990s in many
European and other populations.7
Moreover, in the USA, the CVD risk
associated with obesity is now lower
than before, and this is not solely
because of the better clinical manage-
ment of CVD risk factors or the lower
prevalence of smoking.6
Further, since the early 1980s, coron-
ary heart disease mortality rates have
halved and life expectancy has increased
steadily in several developed countries.8
However, obesity has increased in these
countries over the same time period.
These differing trends are difficult to
reconcile with the supposedly potent
impact, at the ‘population’ level, of
overweight and obesity on CVD or life
expectancy. At the most, the increase in
obesity may have slowed down the
favourable trends of reduced mortality
and increased life expectancy.
In several high-income countries, a
levelling off of the previously falling
CVD rates was recently observed in
young adults;8 some argued that it is
due to obesity trends. However, this
might also reflect that most CVD cases
in young adults are now sporadic,
at least in the wealthier segments of
the population: a lower epidemiological
plateau may have been reached (floor
effect) and further reduction of the
low absolute rates of CVD may be not
possible. In any case, it is unlikely
that the current BMI trends will
push the CVD rates back to the high
values observed in the 1960s. Obesity
is probably not a key player in CVD
trends.
Nevertheless, it is clear that obesity
does have a large impact on the epi-
demiology of several important condi-
tions, especially diabetes. A further and
often neglected consequence of obesity
is chronic disabilities, resulting from
conditions strongly associated with
obesity such as diabetes and osteoarth-
ritis.6 Chronic disabilities may also
be more severe than before because
overweight tends to appear at younger
age and lasts for a long time. Potentially,
disabilities may be the most substantial
public health consequence of obesity,
conducing to a decline of healthy ageing
and a corresponding increase of the
costs of health and social services.
Causality of obesity on
associated conditions
Historically, overweight was first found
to be a marker of high risk of death
in life insurance cohorts, used to deter-
mine premiums. Insurers were not
interested by knowing whether over-
weight was causally related or not to any
diseases; overweight was merely a risk
marker.
How BMI is associated with the risk
of chronic disease or mortality is vividly
debated. Unlike the monotonic upward
(log-linear) risk of mortality associated
with many CVD risk factors, there is
a U-shaped relationship between BMI
and mortality.9
While severe obesity (i.e. BMI >35
or 40 kg/m2) is clearly associated with
chronic diseases and with a reduced
lifespan,9 slightly elevated BMI may
be protective,10 in particular in elderly.
Actually, the ‘ideal’ BMI is likely to vary
across populations, to differ between
male and female, to change with age
and, maybe, to have changed over
time.10 A consequence for population-
based prevention strategies is that shift-
ing the whole BMI distribution towards
lower values is not appropriate since low
BMI is associated with increased
mortality.
Several physiopathological mechan-
isms, suggesting a causal effect, have
linked excess adiposity to a variety
of diseases. However, corpulence is a
proxy for many variables2 which may be
difficult to tease. The association be-
tween obesity and a specific disease (e.g.
CVD) may be confounded by numerous
factors, socio-economic status being one
of them. Potentially, any association
between obesity and the disease may be
due to factors leading to both rather
than being a genuine causal effect of
obesity itself.11 For instance, low phys-
ical activity may cause both obesity and
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CVD; in this case, obesity is a by-
product of low physical activity or, at
the most, an intermediate outcome
between low physical activity and CVD.
Further, to demonstrate the causal
effect of an exposure (obesity) on an
outcome (a specific disease), the key
is to identify ‘interventions’ that are able
to reduce the exposure (obesity) initially
and the outcome (say, CVD) conse-
quentially.11 Currently, we are short in
terms of evidence because we still lack
well-defined interventions to modify the
mean level and distribution of BMI in
populations.
Nosological status of
obesity
Another issue is the nosological status
of obesity. The call to consider obesity
(defined as high BMI) a ‘disease’ rather
than a ‘risk factor’ is based on a
‘utilitarian perspective’,12 the argument
being that labelling obesity a disease
may potentially help to solicit resources
into prevention, treatment and research
of obesity, and to reduce stigma and
discrimination of obese persons.12
However, shifting from the status of
obesity as a ‘risk factor’ to obesity as
a ‘disease’ may not help understand the
public health stakes of obesity. The
status of risk factor only implies a
probabilistic notion for a risk associated
with a given BMI, which is undis-
putable, but does not require any agree-
ment on the essence of obesity or on
causal mechanisms linking obesity and
related diseases. Critical is the fact that
there is no clear-cut difference between
obese and non-obese states. The exist-
ence of ‘healthy obese’, i.e. obese with
normal cardio-metabolic profile and no
co-morbidities, questions the validity of
labelling obesity as a disease. Healthy
obesity also opens stimulating avenues
for a better understanding of
physiopathological mechanisms of
obesity-associated diseases and for the
potential benefit of health promotions
in obese persons.
More data and less
modelling to prevent the
obesity booga booga
Dramatization of overweight and obes-
ity is unlikely to help the public health
management of the problem. We sug-
gest that the word ‘epidemic’ should not
to be used to describe rising obesity
trends. An epidemic is an occurrence of
diseases that is temporarily of high
prevalence in a population. By the late
20th century, the definition has been
extended to include the increasing
prevalence of some risk factors.
However, the word epidemic often
implies ‘an impending danger and a
large number of victims’.13 Still, it is
arguable that a large number of victims
are caused by overweight and obesity
and, more importantly, would all be
avoided if the mean BMI was reduced.
The flourishing number of modelling
studies is also problematic and may be
misleading. For instance, to quantify the
potential benefit of obesity prevention,
the attributable fraction of high BMI
is often computed. For a given disease,
the attributable fraction provides the
proportion of diseased persons in the
population that could be avoided if all
the excess risk associated with high BMI
was eliminated.14 Strictly speaking, this
presupposes a hypothetical intervention
thanks to which the obese people never
became obese and were always like non-
obese.14 However, such intervention
does not exist and, in fact, the attribut-
able fraction does not accurately inform
policy on the disease burden which
would be eliminated if high BMI was
prevented.11,14 For policymakers, the
key is to get operational interventions
to reduce BMI. Different interventions,
e.g. diet and physical activity vs
drugs and surgery, will not reduce
the burden of diseases associated
with obesity to the same extent.11
Obviously, we can not assess with confi-
dence the effect of such interventions
on the burden of associated diseases.
Modelling helps but is not sufficient
to anticipate the consequences of obesity
and, above all, to prioritize decisions in
health policy with the current level of
knowledge.
We argue that the effects of over-
weight and obesity rising trends still
have to be better evaluated at a popu-
lation level. In European countries,
national surveys are needed to assess
the distribution of overweight and obes-
ity (using BMI and, naturally, other
tools to assess adiposity) and the burden
of associated conditions, including
chronic disabilities. It is also crucial to
evaluate the appropriateness and the
impact of pharmacological treatments of
risk factors which are prescribed on a
massive scale in the obese but subject-
ively healthy individuals.15 Dieting
habits also need to be better described.
A new international initiative, similar
to what was done for MONICA for
CVD, could help assess the real nature
of the ‘epidemic’ we are facing. Coupled
with the evaluations of prevention
strategies, these data would help assess
the consequences of obesity at popula-
tion level and what could be the real
benefit of obesity prevention.
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